본문 바로가기
KERD
논문KCI 등재

Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”

Yoshihiro Kamada|Hideki Fujii|Michihiro Iwaki
대한간학회 (The korean Association for the Study of the Liver)|2024.04|Clinical and Molecular Hepatology|제30권 제2호|pp. 281-283|DOI 10.3350/cmh.2024.0214

1

조회

0

다운로드

3

인용

0

참고문헌

키워드

Cardiovascular diseaseLiver biopsyCardiometabolic criteria

참고문헌 (13)

  1. Iwaki M, "Prognosis of biopsy-confirmed MASLD : A sub-analysis of the CLIONE study", Clin Mol Hepatol, 30, pp.225~234 (2024)
  2. Fujii H, "Clinical outcomes in biopsy-proven nonalcoholic fatty liver disease patients : A multicenter registry-based cohort study", Clin Gastroenterol Hepatol, 21, pp.370~379 (2023)
  3. Oh JH, "Clinical impact of five cardiometabolic risk factors in MALSD : Insights into regional and ethnic differences", Clin Mol Hepatol, 30, pp.168~170 (2024)
  4. Arafa A, "Fatty liver index as a proxy for non-alcoholic fatty liver disease and the risk of stroke and coronary heart disease : The suita study", J Stroke Cerebrovasc Dis, 33, pp.107495~ (2024)
  5. Leung JC, "Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients", Hepatology, 65, pp.54~64 (2017)
  6. Le MH, "Global incidence of adverse clinical events in non-alcoholic fatty liver disease : A systematic review and meta-analysis", Clin Mol Hepatol, 30, pp.235~246 (2024)
  7. Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)
  8. Tokushige K, "Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease", nonalcoholic steatohepatitis 2020, 2021, pp.56, 951~963
  9. Rinella ME, "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease", Hepatology, 77, pp.1797~1835 (2023)
  10. Bea S, "Outcomes of SGLT-2i and GLP-1RA therapy among patients with type 2 diabetes and varying NAFLD status", JAMA Netw Open, 6, pp.e2349856~ (2023)
  11. Noureddin M, "MASH clinical trials and drugs pipeline : An impending Tsunami", Hepatology (2024)[DOI]
  12. Jang H, "Outcomes of various classes of oral antidiabetic drugs on nonalcoholic fatty liver disease", JAMA Intern Med (2024)[DOI]
  13. Harrison SA, "A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis", N Engl J Med, 390, pp.497~509 (2024)

관련 논문AI추천

Reply to correspondence on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”Dae Won Jun, Eileen Laurel Yoon대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호Correspondence to editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunc tion-associated steatotic liver disease”Hye Won Lee, Seung Up Kim대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: A sub-analysis of the CLIONE study”Jie Li, Junping Shi, Wenjing Ni, Xiaoyan Ma, Yee Hui Yeo, Yixuan Zhu대한간학회 · Clinical and Molecular Hepatology2024 · 제30권 제4호Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”Do Seon Song, Jin Mo Yang, U Im Chang대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”Chuan Liu, Gao-Jun Teng, Hong You, Ling Yang, Xiaolong Qi대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Correspondence on Editorial regarding “Baveno- VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients”Giulia Tosetti, Massimo Primignani, Sanchit Sharma, Xiaolong Qi, Yu Jun Wong대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호

이 간행물의 다른 논문 (31건)

Comprehensive approach to controlling chronic hepatitis B in ChinaJidong Jia, Shan Shan, Xinyan Zhaopp. 135-143Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answerMing-Lung Yu, Pin-Nan Chengpp. 144-146Toward hepatitis C virus elimination using artificial intelligenceJeong-Hoon Lee, Moon Haeng Hurpp. 147-149Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomizationJu Dong Yang, Mohammad Saeid Rezaee-Zavareh, Naomy Kimpp. 150-153Enhancing off-nucleos(t)ide analogue outcome predictions in chronic hepatitis B with time-varying hepatitis B core-related antigenChen-Te Huang, Tai-Chung Tsengpp. 154-156
원문 보기